PD-1/PD-l1 blockades in non-small-cell lung cancer therapy

OncoTargets and Therapy

Volumn 9, Issue , 2016, Pages 489-502

  Jing, Wang ^a,b   Li, Miaomiao ^c   Zhang, Yan ^b   Teng, Feifei ^b   Han, Anqin ^b   Kong, Li ^b   Zhu, Hui ^b  

^a WEIFANG MEDICAL UNIVERSITY   (China)

^b SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^c SHANDONG MEDICAL COLLEGE   (China)

Author keywords

Checkpoint; Immunotherapy; NSCLC; PD 1; PD L1

Indexed keywords

AFATINIB; ATEZOLIZUMAB; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DOCETAXEL; DURVALUMAB; ERLOTINIB; GEFITINIB; GEMCITABINE; IPILIMUMAB; NECITUMUMAB; NIVOLUMAB; PACLITAXEL; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TICILIMUMAB;

ANEMIA; ANTINEOPLASTIC ACTIVITY; BRAIN ISCHEMIA; BYSTANDER EFFECT; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CANDIDEMIA; CD8+ T LYMPHOCYTE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEASIBILITY STUDY; HUMAN; HYPERTRANSAMINASEMIA; HYPOXIA; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MYALGIA; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RECEPTOR BLOCKING; REVIEW; THROMBOCYTOPENIA; TUMOR ASSOCIATED LEUKOCYTE;

EID: 84957536816     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S94993     Document Type: Review

References (80)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90
2. Howington JA, Blum MG, Chang AC, Balekian AA, Murthy SC. Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143(5 Suppl):e278S–e313S
3. Nagata Y, Hiraoka M, Shibata T, et al. A phase II trial of stereotactic body radiation therapy for operable T1N0M0 non-small cell lung cancer: Japan clinical oncology group (JCOG0403). Int J Radiat Oncol Biol Phys. 2010;78(3):S27–S28
4. Spiro SG, Gould MK, Colice GL; American College of Chest P. Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest. 2007;132(3 Suppl):149S–160S
5. Ettinger DS, Akerley W, Borghaei H, et al. Non-small cell lung cancer. J Natl Compr Canc Netw. 2012;10(10):1236–1271
6. Thomas A, Hassan R. Immunotherapies for non-small-cell lung cancer and mesothelioma. Lancet Oncol. 2012;13(7):e301–e310
7. Younes RN, Pereira JR, Fares AL, Gross JL. Chemotherapy beyond first-line in stage IV metastatic non-small cell lung cancer. Rev Assoc Med Bras. 2011;57(6):686–691
8. seer.cancer.gov [homepage on the Internet]. SEER stat fact sheets: lung and bronchus cancer [updated August 20, 2015; cited October 31, 2015]. Available from: http://seer.cancer.gov/. Accessed October 31, 2015
9. Barlesi F, Scherpereel A, Gorbunova V, et al. Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial. Ann Oncol. 2014;25(5):1044–1052
10. National Comprehensive Cancer Network. Fort Washington.@National Comprehensive Cancer Network, Inc; 2015. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#nscl. Accessed October 23, 2015
11. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704
12. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793–800
13. Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, Nishimura M. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res. 2004;10(15):5094–5100
14. Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci U S A. 2001;98(24):13866–13871
15. Sheppard KA, Fitz LJ, Lee JM, et al. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett. 2004;574(1–3):37–41
16. Lesterhuis WJ, Steer H, Lake RA. PD-L2 is predominantly expressed by Th2 cells. Mol Immunol. 2011;49(1–2):1–3
17. Zhang Y, Huang S, Gong D, Qin Y, Shen Q. Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer. Cell Mol Immunol. 2010;7(5):389–395
18. Taube JM. Unleashing the immune system: PD-1 and PD-Ls in the pre-treatment tumor microenvironment and correlation with response to PD-1/PD-L1 blockade. Oncoimmunology. 2014;3(11):e963413
19. Gettinger SN, Hellmann MD, Shepherd FA, et al. First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression. J Clin Oncol. 2015;33(15 Suppl):8025
20. Rizvi NA, Mazieres J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16(3):257–265
21. Carbognin L, Pilotto S, Milella M, et al. Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PLoS One. 2015;10(6):e0130142
22. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–2028
23. Rizvi NA, Garon EB, Leighl N, et al. Optimizing PD-L1 as a biomarker of response with pembrolizumab (pembro; MK-3475) as first-line therapy for PD-L1-positive metastatic non-small cell lung cancer (NSCLC): updated data from KEYNOTE-001. J Clin Oncol. 2015;33(15 Suppl):8026
24. Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563–567
25. Horn L, Spigel DR, Gettinger SN, et al. Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (antiPDL1) in non-small cell lung cancer (NSCLC): update from a phase Ia study. J Clin Oncol. 2015;33(15 Suppl):8029
26. Spigel DR, Chaft JE, Gettinger SN, et al. Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1selected patients with non-small cell lung cancer (NSCLC). J Clin Oncol. 2015;33(15 Suppl):8028
27. Merck Sharp & Dohme Corp. Study of pembrolizumab (MK-3475) in participants with advanced non-small cell lung cancer (MK-3475025/KEYNOTE-025). Available from: https://www.clinicaltrials.gov/ct2/show/NCT02007070. NLM identifier: NCT02007070. Accessed November 28, 2015
28. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–135
29. Paz-Ares L, Horn L, Borghaei H, et al. Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). J Clin Oncol. 2015;33(18 Suppl):LBA109
30. Jiang L, Zhao Z, Jiang S, et al. Immunological markers predict the prognosis of patients with squamous non-small cell lung cancer. Immunol Res. 2015;62(3):316–324
31. Pan ZK, Ye F, Wu X, An HX, Wu JX. Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis. J Thorac Dis. 2015;7(3):462–470
32. Wang A, Wang HY, Liu Y, et al. The prognostic value of PD-L1 expression for non-small cell lung cancer patients: a meta-analysis. Eur J Surg Oncol. 2015;41(4):450–456
33. Llosa NJ, Cruise M, Tam A, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015;5(1):43–51
34. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatchrepair deficiency. N Engl J Med. 2015;372(26):2509–2520
35. Li M, Zhang Q, Liu L, et al. Expression of the mismatch repair gene hMLH1 is enhanced in non-small cell lung cancer with EGFR mutations. PLoS One. 2013;8(10):e78500
36. Slovakova P, Majerova L, Matakova T, Skerenova M, Kavcova E, Halasova E. Mismatch repair gene polymorphisms and association with lung cancer development. Adv Exp Med Biol. 2015;833:15–22
37. Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412–7420
38. Nishino M, Giobbie-Hurder A, Gargano M, Suda M, Ramaiya NH, Hodi FS. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res. 2013;19(14):3936–3943
39. Kerr KM, Tsao MS, Nicholson AG, et al. Programmed death-ligand 1 immunohistochemistry in lung cancer: in what state is this art? J Thorac Oncol. 2015;10(7):985–989
40. Jia M, Feng W, Kang S, et al. Evaluation of the efficacy and safety of antiPD-1 and anti-PD-L1 antibody in the treatment of non-small cell lung cancer (NSCLC): a meta-analysis. J Thorac Dis. 2015;7(3):455–461
41. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26): 2443–2454
42. Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2015;33(18):2004–2012
43. Bauer TM, McCleod M, Chandler JC, et al. An ongoing phase IIIb/IV safety trial of nivolumab (NIVO) in patients (pts) with advanced or metastatic non-small-cell lung cancer (NSCLC) who progressed after receiving 1 or more prior systemic regimens. J Clin Oncol. 2015;33(15 Suppl):3013
44. Merck Sharp & Dohme Corp. Study of MK-3475 (pembrolizumab) versus platinum-based chemotherapy for participants with PD-L1positive advanced or metastatic non-small cell lung cancer (MK-3475042/KEYNOTE-042). Available from: https://www.clinicaltrials.gov/ ct2/show/NCT02220894. NLM identifier: NCT02220894. Accessed November 28, 2015
45. Merck Sharp & Dohme Corp. Study of pembrolizumab (MK-3475) compared to platinum-based chemotherapies in participants with metastatic non-small cell lung cancer (MK-3475-024/KEYNOTE-024). Available from: https://www.clinicaltrials.gov/ct2/show/NCT02142738. NLM identifier: NCT02142738. Accessed November 28, 2015
46. Spira AI, Park K, Mazieres J, et al. Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR). J Clin Oncol. 2015;33(15 Suppl):8010
47. AstraZeneca. A global study to assess the effects of MEDI4736 in patients with locally advanced or metastatic non small cell lung cancer (ATLANTIC). Available from: https://www.clinicaltrials.gov/ct2/show/NCT02087423. NLM identifier: NCT02087423. Accessed November 28, 2015
48. Rizvi NA, Chow LQM, Dirix LY, et al. Clinical trials of MPDL3280A (anti-PDL1) in patients (pts) with non-small cell lung cancer (NSCLC). J Clin Oncol. 2014;32(15 Suppl):TPS8123
49. Papadimitrakopoulou V, Patnaik A, Borghaei H, et al. Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C. J Clin Oncol. 2015;33 (15 Suppl):8031
50. Liu SV, Powderly JD, Camidge DR, et al. Safety and efficacy of MPDL3280A (anti-PDL1) in combination with platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2015;33(15 Suppl):8030
51. Antonia SJ, Brahmer JR, Gettinger SN, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2014;32(15 Suppl):8113
52. Jyoti Patel. Carboplatin/Nab-Paclitaxel and MK-3475 in NSCLC. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02382406. NLM identifier: NCT02382406. Accessed November 28, 2015
53. Providence Health & Services. MK-3475 and gemcitabine in non-small cell lung cancer (NSCLC). Available from: https://www.clinicaltrials.gov/ct2/show/NCT02422381. NLM identifier: NCT02422381. Accessed November 28, 2015
54. European Thoracic Oncology Platform. NIvolumab consolidation after standard first-line chemotherapy and radiotherapy in locally advanced stage IIIA/B NSCLC (NICOLAS). Available from: https://www.clinicaltrials.gov/show/NCT02434081. NLM identifier: NCT02434081. Accessed November 28, 2015
55. Nasser Hanna MD. Consolidation pembrolizumab (MK-3475) following chemoradiation in patients with inoperable/unresectable stage III NSCLC. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02343952. NLM identifier: NCT02343952. Accessed November 28, 2015
56. Chen N, Fang W, Zhan J, et al. Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driven NSCLC: implication for optional immune targeted therapy for NSCLC patients with EGFR mutation. J Thorac Oncol. 2015;10(6):910–923
57. Akbay EA, Koyama S, Carretero J, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013;3(12):1355–1363
58. D’Incecco A, Andreozzi M, Ludovini V, et al. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br J Cancer. 2015;112(1):95–102
59. Lin C, Chen X, Li M, et al. Programmed death-ligand 1 expression predicts tyrosine kinase inhibitor response and better prognosis in a cohort of patients with epidermal growth factor receptor mutation-positive lung adenocarcinoma. Clin Lung Cancer. 2015;16(5): e25–e35
60. Tang Y, Fang W, Zhang Y, et al. The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced nonsmall cell lung cancer patients treated with EGFR-TKIs. Oncotarget. 2015;6(16):14209–14219
61. Creelan BC, Chow LQ, Kim D-W, et al. Safety and tolerability results from a phase I study of MEDI4736, a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib in patients (pts) with non-small-cell lung cancer (NSCLC). J Clin Oncol. 2015; 33(15 Suppl):3047
62. Rizvi NA, Antonia SJ, Shepherd FA, et al. Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) maintenance as monotherapy or in combination with bevacizumab (BEV) for non-small cell lung cancer (NSCLC) previously treated with chemotherapy. Int J Radiat Oncol Biol Phys. 2014;90(5):S32
63. Thatcher N, Hirsch FR, Luft AV, et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2015;16(7):763–774
64. Paz-Ares L, Mezger J, Ciuleanu TE, et al. Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. Lancet Oncol. 2015;16(3):328–337
65. Eli Lilly and Company. A study of the combination of necitumumab (LY3012211) and pembrolizumab (MK3475) in participants with NSCLC. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02451930. NLM identifier: NCT02451930. Accessed November 28, 2015
66. Callahan MK, Ott PA, Odunsi K, et al. A phase 1 study to evaluate the safety and tolerability of MEDI4736, an anti-PD-L1 antibody, in combination with tremelimumab in patients with advanced solid tumors. J Clin Oncol. 2014;32(15 Suppl):TPS3120
67. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34
68. Ott PA, Callahan MK, Odunsi K, et al. A phase I study to evaluate the safety and tolerability of MEDI4736, an anti-programmed cell deathligand-1 (PD-L1) antibody, in combination with tremelimumab in patients with advanced solid tumors. J Clin Oncol. 2015;33(15 Suppl): TPS3099
69. AstraZeneca. A global study to assess the effects of MEDI4736, given as monotherapy or in combination with tremelimumab determined by PD-L1 expression versus standard of care in patients with locally advanced or metastatic non small cell lung cancer (ARCTIC). Available from: https://www.clinicaltrials.gov/ct2/show/NCT02352948. NLM identifier: NCT02352948. Accessed November 28, 2015
70. Finkelstein SE, Timmerman R, McBride WH, et al. The confluence of stereotactic ablative radiotherapy and tumor immunology. Clin Dev Immunol. 2011;2011:439752
71. Hatzi VI, Laskaratou DA, Mavragani IV, et al. Non-targeted radiation effects in vivo: a critical glance of the future in radiobiology. Cancer Lett. 2015;356(1):34–42
72. Melero I, Grimaldi AM, Perez-Gracia JL, Ascierto PA. Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin Cancer Res. 2013;19(5):997–1008
73. Teng F, Kong L, Meng X, Yang J, Yu J. Radiotherapy combined with immune checkpoint blockade immunotherapy: achievements and challenges. Cancer Lett. 2015;365(1):23–29
74. Golden EB, Demaria S, Schiff PB, Chachoua A, Formenti SC. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res. 2013;1(6):365–372
75. Dewan MZ, Galloway AE, Kawashima N, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res. 2009; 15(17):5379–5388
76. Schaue D, Ratikan JA, Iwamoto KS, McBride WH. Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys. 2012;83(4):1306–1310
77. Lee SJ, Jang BC, Lee SW, et al. Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274). FEBS Lett. 2006;580(3):755–762
78. M.D. Anderson Cancer Center. MK-3475 and hypofractionated stereotactic radiation therapy in patients with non-small cell lung cancer (NSCLC). Available from: https://www.clinicaltrials.gov/ct2/show/NCT02444741. NLM identifier: NCT02444741. Accessed November 28, 2015
79. The Netherlands Cancer Institute. Pembrolizumab after SBRT versus pembrolizumab alone in advanced NSCLC (PEMBRO-RT). Available from: https://www.clinicaltrials.gov/ct2/show/NCT02492568. NLM identifier: NCT02492568. Accessed November 28, 2015
80. Yale University. Evaluating the combination of MK-3475 and sterotactic body radiotherapy in patients with metastatic melanoma or NSCLC. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02407171. NLM identifier: NCT02407171. Accessed November 28, 2015.